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Available online 3 September 2016AbstractIncreasing attention has been given to the tumor microenvironment (TME), which includes cellular and structural components such as fi-
broblasts, immune cells, vasculature, and extracellular matrix (ECM) that surround tumor sites. These components contribute to tumor growth
and metastasis and are one reason why traditional chemotherapy often is insufficient to eradicate the tumor completely. Newer treatments that
target aspects of the TME, such as antiangiogenic and immunostimulatory therapies, have seen limited clinical success despite promising
preclinical results. This can be attributed to a number of reasons, including a lack of drug penetration deeper into the necrotic tumor core,
nonspecific delivery, rapid clearance from serum, or toxic side effects at high doses. Nanoparticles offer a potential solution to all of these
obstacles, and many recent studies have shown encouraging results using nanomedicine to target TME vasculature, ECM, and immune response.
While few of these platforms have made it to clinical trials to date, these strategies are relatively new and may offer a way to improve the effects
of anticancer therapies.
Copyright © 2016, Shanghai Hengrun Biomedical Technology Research Institute. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Classically, cancer has been described as a disease
involving uncontrolled cell growth. Now, however, it is
apparent that cancer growth and metastasis are not solely
dependent on the tumor cells themselves, but involve pathol-
ogies in the surrounding tumor microenvironment (TME) as
well. In the 19th century, Stephen Paget's “seed and soil”
hypothesis postulated that cancer “seeds” or metastases pref-
erentially established secondary tumors at specific sites (the* Corresponding author. Mork Family Department of Chemical Engineering
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4“soil”) [1]. Only within the past few decades have researchers
focused on anticancer treatments which target the TME rather
than the actual cancer cells.
The TME contains various cell types, such as fibroblasts,
myofibroblasts, adipocytes, and immune cells, as well as
extracellular matrix (ECM), and blood and lymphatic vascu-
lature [2]. Increasing evidence suggests that the TME is a
crucial part of cancer development, proliferation, and metas-
tasis [3]. The TME also contributes to the failure of many
conventional cancer therapies to completely eradicate the
tumor. Nanomedicine offers a way to circumvent or take
advantage of the properties of the TME. As illustrated in
Fig. 1, this review will discuss nanoparticle-mediated targeting
of TME aspects including vasculature, ECM, and immune
cells, with a focus on modulating the immune response. Select
studies are summarized in Table 1.h Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
Fig. 1. Schematic presentation of components of the tumor microenvironment and nanoparticle therapies. The tumor microenvironment consists of tumor cells as
well as many immunosuppressive cells and tumor-associated macrophages (TAMs), few immunostimulatory lymphocytes, and abundant extracellular matrix
(ECM) and vasculature. Nanoparticle therapies have been shown to inhibit immunosuppressive cells and TAMS and to hinder vascular development. Nanoparticles
can also be targeted to the ECM and can augment lymphocyte numbers and function.
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drug deliveryBlood vessel development is critical for the continued
growth and progression of solid tumors. Unlike normal blood
vessels, structurally and functionally abnormal tumor vascu-
lature impedes the efficient delivery of both oxygen andTable 1
A summary of nanoparticle-mediated therapies targeting properties of the tumor m
Category Description Target and
Vasculature PLGA nanoparticles with combrestatin Inhibits an
antitumor
Polymer nanoparticles with lodamin Inhibits an
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expansiontherapeutics at effective concentrations to all cancer cells
[4e9]. This phenomenon is mainly caused by an imbalance of
pro- and anti-antiangiogenic factors, which leads to endothe-
lial cell proliferation, migration, and new vessel formation.
This contributes to the formation of poorly organized blood
vessels, impaired blood flow, increased hypoxic regions within
the tumor, and higher interstitial fluid pressure (IFP) [9,10].icroenvironment.
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agents such as doxorubicin
Preclinical [20]
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vascular and interstitial pressure are not maintained, resulting
in elevated interstitial pressure within the tumor. Reduced
lymphatic drainage from the tumor further exacerbates
elevated IFP within the tumor. High IFP hinders effective
penetration of anticancer agents into the deeper core of solid
tumors [10].
Due to the leaky tumor vasculature, nanoparticles can
accumulate within the tumor and its surrounding environment
more effectively than free drugs. This phenomenon, referred to
as the enhanced permeability and retention (EPR) effect, is
further enhanced by poor lymphatic drainage around the
tumor, effectively trapping the nanoparticles at the site [11].
Recent studies also demonstrate that anti-angiogenic or anti-
vasculature therapies have shown promising results in
enhancing drug delivery and boosting anticancer efficacy
[4,8e10,12]. The combination of passive targeting via the
EPR effect and active targeting with an anti-angiogenic con-
jugate confers an advantage of nanoparticle-mediated thera-
pies over soluble drugs.1.2. Abnormalities of tumor ECM and effects on tumor
progressionMajor ECM components include collagen, glycoproteins,
proteoglycans, elastin, and hyaluronan as well as ECM-
associated enzymes and growth factors which direct cell pro-
liferation and differentiation [13]. However, in a hypoxic
TME, biophysical and biological characteristics of the ECM
are altered, contributing to tumor progression, invasion, and
metastasis. Stromal stiffness is significantly increased in breast
tumor tissue stroma as compared to normal tissue stroma
[6,7,14]. Lysyl oxidase (LOX) is a major player that upregu-
lates crosslinking of collagen fibers with other ECM compo-
nents [14]. Furthermore, the interstitial space is mostly
composed of collagen. In the TME, the collagen content is
higher than that of normal tissue and is a major barrier of
interstitial drug penetration [13]. Interactions between cancer
cells and the various components of the ECM serve as one of
the main obstacles that prevents effective penetration of
chemotherapeutic drugs into tumor tissue.1.3. Immune dysfunction and opportunities for
nanomedicine in the TMEThe TME contributes to chronic inflammation and dysre-
gulation of immune cells. In a healthy individual, both innate
and adaptive immune cells partake in cancer immuno-
surveillance. In the TME, chronic exposure to inflammatory
cytokines often results in immune cell anergy and a lack of
antitumor response. Over time, these immune cells themselves
start to secrete pro-tumorigenic mediators and contribute to
maintaining the TME. Immune suppressor cells also accu-
mulate within the TME.
T cells are part of the adaptive immune system that have
antitumor effects, but are suppressed in the TME.
Foxp3þCD25þCD4þ regulatory T cells (Tregs) are recruited tothe tumor site and secrete inhibitory cytokines such as IL-10
and transforming growth factor-b (TGF-b) [15]. Myeloid-
derived suppressor cells dampen immune responses by hin-
dering antigen presentation by dendritic cells (DCs) and
impairing CD8þ T cell cytotoxicity [16].
The TME also impacts the function of innate immune cells,
including DCs and natural killer (NK) cells. DCs are antigen-
presenting cells which stimulate T cell response to tumor
antigens. DCs pulsed with tumor peptides are being researched
as a cancer vaccine, but have seen limited clinical efficacy due
to the inhibitory effects of the TME [17]. Rather than being
activated by an antigen-specific receptor, NK cells are stimu-
lated by a complex balance of inhibitory and stimulatory
signals. Under normal conditions, their cytotoxic abilities are
inhibited by engaging with HLA class I present on healthy
autologous cells. Tumors tend to downregulate HLA class I,
leaving NK cells uninhibited and able to target the cancer
cells. In the TME, cancer cells are often able to escape NK
cytotoxicity by suppressing NK cells with IL-10 and TGF-b
[18].
Macrophages play roles in both the innate and adaptive
immune systems. Macrophages with the M1 phenotype have
enhanced cytotoxicity and contribute to an inflammatory
environment by upregulating the release of pro-inflammatory
cytokines and reactive oxygen species. Within the TME,
macrophages can be polarized from the M1 to the immuno-
suppressive M2 phenotype [17]. Tumor-associated macro-
phages (TAMs) can also modulate the ECM by signaling to
increase collagen secretion or by releasing matrix metal-
loproteases (MMPs), which break down ECM and can lead to
metastasis. Additionally, TAMs can secrete proangiogenic
factors and contribute to tumor vascularization [19]. All of
these functions make TAMs an important target in cancer
immunotherapy.
Numerous studies have used nanoparticles to carry immu-
nomodulatory agents and affect various immune cell pop-
ulations, including DCs [20] and T cells [21e23]. While many
of these have been used in the treatment of autoimmune dis-
eases with the goal of suppressing the immune system, the
same nanoparticle platforms can apply to anticancer, immu-
nostimulatory therapies. Depending on their payload, nano-
particles can augment immune responses within the TME as
well as inhibit immunosuppressor cells such as Tregs. Nano-
based delivery systems can reduce undesired toxicities and
rapid clearance rates that have hindered the systemic admin-
istration of free cytokines in the clinic. Targeted nanoparticles
can also deliver their cargo to specific subsets of immune cells
for enhanced antitumor effects.
2. Nanomedicine targeting the tumor microenvironment2.1. Inhibiting angiogenesis for vasculature
normalizationThe EPR effect has been used as the foundation for passive
targeting of nanomedicines to tumor sites. Unique features of
vascular pathophysiology and inefficient lymphatic drainage
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optimal passive targeting strategy of nanoparticles depends on
the degree of tumor vascularization and angiogenesis. As
previously mentioned by Jain et al., the irregular and leaky
tumor vasculature is also responsible for elevated tumor IFP
which could be a barrier for efficient transport of drugs. It is
now well known that most tumors have increased IFP [24].
Furthermore, in order for most malignant solid tumors to
grow and progress, tumors stimulate the formation of new
blood vessels through processes driven primarily by pro-
angiogenic proteins such as vascular endothelial growth fac-
tor (VEGF) [4,5,19]. Upregulation of these proteins influences
endothelial cell migration and proliferation, resulting in excess
endothelial cells and abnormal perivascular cells. Due to this
poor vascularization, conventional intravenously distributed
cytotoxic drugs are limited in their ability to penetrate the
tumor core, posing a significant barrier to their anticancer
efficacy. This therapeutic obstacle has given rise to a different
strategy to cancer treatment: targeting tumor vasculature and
angiogenesis using nanoparticle delivery systems to allow
greater dissemination of chemotherapeutics. Anti-angiogenic
therapies eliminate excess endothelial cells, resulting in
normalization of vasculature. This “normalized” vasculature
has decreased vessel diameter, density and permeability which
lowers interstitial fluid pressure and enhances blood perfusion
and oxygen tension [19,24,25].
Numerous active vasculature targeting approaches using
nanoparticles have emerged to enhance the intracellular con-
centration of drugs in tumor cells. Sengupta et al. developed a
PLGA polymeric nanoscale delivery system targeting tumor
cells and the tumor vasculature. Doxorubicin was covalently
attached to the inner PLGA core, and the anti-angiogenic
agent combretastatin was encapsulated within the outside
lipid envelope. Both doxorubicin and combrestatin were suc-
cessfully encapsulated into their ‘nanocell’ delivery system,
enabling the temporal release of two drugs more effectively
than with free drugs or simple liposomal formulations. As a
result, combrestatin released from the outer envelope was able
to induce a rapid vascular shutdown inside the tumor by dis-
rupting the cytoskeletal structures, which first took advantage
of the EPR effect and then further trapped the nanoparticles
within the tumor after disrupting tumor vasculature. After-
ward, doxorubicin from the inner nanoparticle was efficiently
taken up by the tumor, improving overall therapeutic index
with reduced toxicity [25].
Another study by Benny et al. synthesized nanopolymeric
micelles loaded with the angiogenesis inhibitor TNP-470,
called Lodamin, and successfully demonstrated improved
oral bioavailability, inhibition of tumor growth, angiogenesis
and proliferation, without causing any severe side effects
in vivo. Tumor growth was significantly decreased upon
treatment with Lodamin compared to the free inhibitor, TNP-
470 [26]. These studies highlight the uses of nanoparticles by
using the EPR effect to prolong the retention of anti-
angiogenic and chemotherapeutic agents within the tumor
and by increasing the bioavailability and vascular uptake of
poorly soluble anti-angiogenic small molecule drugs.2.2. Targeting tumor extracellular matrixAbnormally dense ECM can cause inefficient penetration
of drugs. TME-associated ECM serves as a guiding scaffold
for cancer cell proliferation, migration, invasion and angio-
genesis [8]. Collagen, the main structural protein of the ECM,
can build migration tracks for the tumor cells. Hyaluronic acid
(HA) contributes to high IFP, preventing the diffusion and
penetration of drugs [7,13,27]. To this end, one of strategies
used to improve intratumoral drug delivery with nanoparticles
is modification of ECM components. Recent studies, along
with clinical trials, have shown that ECM-degrading enzymes,
such as collagenase or hyaluronidase, can improve nano-
particle penetration into solid tumors. However these agents
have potential risk of increasing tumor metastasis. A PEGy-
lated form of recombinant human hyaluronidase (PEGPH20)
has recently been introduced into clinical trials combined with
other chemotherapeutics [28]. PEGPH2 was shown to have
therapeutic effects for patients with metastatic pancreatic
cancer, especially those which expressed high levels of hyal-
uronidase. Adverse side effects were mild to moderate and
none led to discontinuation of the treatment. PEGPH20 war-
rants additional studies in combination with other chemo-
therapeutic, in particular for patients with hyaluronidase-
overexpressing tumors.
Further studies have been focusing on enzymes such as
LOX or proteases like MMPs, which are responsible for
remodeling ECM. In the study by Kanapathipillai et al.,
polymeric nanoparticles coated with a LOX inhibitory anti-
body was able to selectively bind to ECM and enhanced
suppression of mammary tumor growth [14]. Using nano-
particles with greatly enhanced therapeutic effects of anti-
LOX antibodiesdin vitro, nanoparticle-bound anti-LOX was
effective at doses 50 times lower than that of soluble anti-
LOX, and had a high therapeutic index in vivo as well.
Another recent study used paclitaxel-loaded PLA nano-
particles which contained a fibronectin-targeting peptide.
Fibronectin is one of the main components of ECM, which is
abundant in the glioma microenvironment. Mice treated with
these targeted nanoparticle-drug conjugates had a survival
time nearly 70% greater than other treatment groups [29].
Nanoparticle-assisted targeting of the tumor ECM is a novel
approach, and although currently few researchers have studied
this potential therapy, it shows significant promise and merits
further study.2.3. Modulating immune response
2.3.1. Administration of general immunostimulatory
cytokines
Many of the immunosuppressive effects of the TME stem
from an imbalance between suppressive and stimulatory cy-
tokines. While cytokine administration has been largely
effective in modulating immune responses in animal models,
these successes have not been translated into clinical results
due to nonspecific delivery and adverse side effects [30]. For
example, IL-2 has been used as a single agent in cancer
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metastatic melanoma and renal cell cancer. However, systemic
administration carries the risk of serious side effects such as
thrombocytopenia and lymphopenia [31]. Additionally, cyto-
kines are often degraded and rapidly cleared from serum [32].
Nanoparticles may offer sustained, specific delivery of cyto-
kines, in part via their passive accumulation within leaky
tumor vasculature.
One early study used liposomes to encapsulate TNFa and,
after confirming that the liposomal TNFa had comparable
in vitro cytotoxicity to free TNFa, suggested using this strat-
egy to improve systemic cytokine anticancer therapy [33].
Since then, many researchers have reported improved circu-
lation times and antitumor effects of cytokines using liposome
carriers. Incorporating IL-2 into multilamellar liposome vesi-
cles prolonged circulation times and decreased hematologic
toxicities when administered intravenously to rats [34]. Cy-
tokines can have a synergistic effect when administered with
conventional chemotherapeutic drugs; dramatic tumor
shrinkage was observed in rats injected with Doxil and lipo-
somes containing TNFa, even though either treatment alone
only resulted in slowed tumor growth [35].
Directly injecting nanoparticle-cytokine formulations into
the tumor have also yielded encouraging results. Polylactic
acid (PLA) microspheres encapsulating IL-12 or GMCSF
were intratumorally injected into mice bearing subcutaneous
tumors, and a combination of the two cytokines yielded the
best results, including fewer metastases and longer survival
times following a single injection [36]. Intratumoral injections
of PLA microspheres carrying either IL-12 or TNFa in B16
melanoma-bearing mice resulted in tumor eradication, induc-
tion of a tumor-specific memory T cell response, and tumor
rejection upon rechallenge [37]. These studies indicate that
nanoparticle-mediated cytokine release can overcome the
immunosuppressive effects of the TME.
2.3.2. Enhancement of T, natural killer, and dendritic cell
function
Instead of stimulating general immune responses via
cytokine delivery, many studies have used nanoparticles to
target specific subsets of immune cells within the TME. T cells
are one of the most common types of immune cell found
within the TME, and higher cytotoxic T cell infiltration is
often correlated with better survival [38], while higher
numbers of Tregs may be associated with worse prognoses
[39]. Given these observations, T cells are a natural target
when remodeling the TME. One group used polyethylene
glycol (PEG) micelles to carry the natural polyphenol, cur-
cumin, to tumor sites in a murine melanoma model. The
curcumin-PEG micelles increased CD8þ T cell cytotoxicity
and decreased numbers of Tregs in vivo. These results were
further augmented when combined with a lipid-based vaccine
containing tumor associated antigens (TAAs) and Toll-like
receptor (TLR) agonist 9. Curcumin is poorly soluble, but its
bioavailability has been improved by nanoparticle platforms,
including liposomes [40], poly(lactic-co-glycolic acid) nano-
particles [41], and NIPAAM-based nanoparticles [42]. Othergroups have focused on targeting Tregs with anti-CD4 anti-
bodies. Anti-CD4 therapy is in clinical trials and inhibits Tregs
immunosuppression, but the high doses required often lead to
unwanted side effects [43]. By utilizing a nanoporous silica
delivery system, one group hypothesized that therapeutic an-
tibodies such as anti-CD4 can be slowly and locally released
into the TME [44].
NKcells have the ability to eradicate tumors, but often are not
abundant in the TME or are suppressed. Nanoparticle-mediated
enhancement of NK function and infiltration into the tumor is a
less common but promising anticancer strategy. Mica has been
shown to possess inherent immunostimulatory properties [45].
Inspired by these findings, one group used mica nanoparticles to
both increase the susceptibility of cancer cells to NK cells and to
increase the numbers and cytotoxicity of NK cells in a murine
breast cancer model [46]. A common strategy to inducing TAA-
dependent cytotoxicity is to pulse DCs with epitopes from the
desired antigens and to inject the DCs as a cancer vaccine,
inducing strong immune responses against the TAA-bearing
cells. Some groups have targeted DCs with nanoparticles in
order to improve their maturation and antigen presenting abili-
ties. TLRs can stimulate DCs, but are hydrophobic and have
short half-lives [47]. Dominguez et al., optimized their cancer
vaccine by covalently conjugating antibodies against RNEU, a
TAA, and against CD40, a surface marker expressed by DCs, to
PLA nanoparticles. The particles trafficked to RNEUþ tumors
and then drew DCs into proximity of the tumor with the anti-
CD40 antibodies. The nanoparticles induced formation of DC-
tumor cell conjugates and rejected 100% of the tumor chal-
lenges [48].
Some of these nanoparticles have immunostimulatory
properties just based on their materials, while others trigger
an immune response due to their cargo. These studies high-
light just a few of the variety of nanoparticle-based therapies
aimed at inhibiting suppressor immune cells or augmenting
the responses of antitumor immune cells.
2.3.3. Improvement of immune responses through targeting
lymph nodes
While many of the aforementioned nanoparticle systems
either circulate in the bloodstream or are targeted to accu-
mulate in the tumor, targeting the lymph nodes is another
important area in which nanoparticles can have a great impact.
Irvine and colleagues have published several papers on poly-
mer nanoparticles which traffic to lymph nodes. For cancer
vaccines to have greater therapeutic effects, vaccine adjuvants
must accumulate in lymph nodes, where naïve B and T cells
are primed. CpG is a DNA motif which binds TLR9 and has
the potential to be a potent immunostimulant; however, free
CpG does not accumulate in lymph nodes. Irvine et al., con-
jugated CpG to a lipophilic albumin-binding domain and
demonstrated that these nanoparticle-based subunit vaccines
traffic to lymph nodes via albumin hitchhiking. One week after
injection, albumin-binding CpG-liposomes accumulation was
six times greater than that of soluble CpG in lymph nodes, and
this platform also led to sustained tumor regression in murine
melanoma models [49].
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their potency, but rapid vaccine clearance remains problem-
atic. Irvine and coworkers combined nanoparticle-based vac-
cines with intralymph node injections to circumvent this issue.
Combining intralymph node vaccination techniques with a
PLGA micro- or nanoparticle-conjugated TLR3 agonist
increased accumulation in lymph nodes, boosted T cell cyto-
kine production, and resulted in more persistent DC activation
in immunized mice.
In contrast, Swartz and colleagues intradermally injected
lymph node-targeting nanoparticle-conjugated TAA and
adjuvant in tumor-bearing mice. Despite the different route of
delivery, these nanoparticles efficiently accumulated in the
lymph nodes. Furthermore, the vaccine had greater therapeutic
effects when conjugated to nanoparticles and when injected
into the TAA-primed tumor-draining lymph node. The
immunosuppressive environment of the tumor-draining lymph
nodes was reversed to a more immunogenic environment after
vaccine administration [50]. Swarz et al., also delivered hy-
drophobic DC stimulatory agents including TLR9 agonist and
paclitaxel, a TLR4 agonist, using pyridyl disulfide nano-
particles targeted to the tumor-draining lymph nodes. They
observed increased DC maturation, greater IL-12 production,
and slowed tumor growth using this delivery system [51].
These studies indicate that functionalized nanoparticles
have the ability to deliver cancer vaccines adjuvants to lymph
nodes and augment immune responses utilizing a variety of
routes of delivery. Utilizing nanoparticles can increase circu-
lation time of the adjuvants due to the larger size of the
complex, and functionalized particles can actively target
crucial areas such as the lymph nodes.
2.3.4. Targeting of tumor associated macrophages
Macrophages are involved in both innate and adaptive
immunity and can be pro- or anti-tumorigenic, depending on
the signals they receive from the surrounding environment. In
the TME, pro-tumorigenic M2 macrophages, or TAMs, sup-
press cancer immunosurveillance and also promote vascular-
ization. Nanoparticle-based therapies can either neutralize or
kill off TAMs entirely or polarize TAMs to a more antitumor
M1 phenotype.
One of the challenges with killing TAMs is to reduce the
TAM population while leaving the anti-tumorigenic M1 pop-
ulation intact. Zhu and colleagues created a delivery system
that was preferentially taken up by TAMs. The desired cargo
can be loaded into mannose-modified PLGA nanoparticles and
shielded by pH-sensitive PEG, which are shed in the acidic
TME to release the drugs to TAMs which overexpress
mannose receptors [52]. Another group reported that PEGy-
lated cowpea mosaic virus nanoparticles (composed of viral
capsid proteins but no viral nucleic acids) were internalized by
TAMs but not M1 macrophages. They suggested that these
nanoparticles can be loaded with cytotoxic agents that target
the TAM population only, with the M1 population rising as the
TAMs decrease [53].
Rather than ablating or inhibiting TAMs, small interfering
RNA (siRNA) technology has been used in recent studies tochange the TAM phenotype. One group demonstrated the
ability of their nanoparticle system to deliver siRNA to TAMs.
They developed a triblock polymer nanoparticle composed of
a pH responsive block surrounded by a protective shell; this
system was functionalized with a TAM-targeting mannose
ligand and was able to deliver siRNA effectively in vivo [54].
Zhang et al., used siRNA targeting macrophage migration
inhibitory factor (MIF), which is upregulated in TAMs.
Glucan-based nanoparticles loaded with anti-MIF siRNAwere
injected into tumor-bearing mice and significantly reduced
tumor growth and metastasis while polarizing TAMs to a more
immunogenic phenotype. After treatment, the TAMs
expressed fewer M2 markers and more pro-inflammatory cy-
tokines such as TNFa and IL-2, which subsequently enhanced
T cell infiltration and function at the tumor site [55]. This may
be a more effective method, as TAMs are converted into cells
with an antitumor response instead of simply being eliminated.2.4. Enhancing antitumor effects with combination
therapiesPerhaps a more successful approach to anticancer therapy
would be to target a combination of the vascular, ECM, and
immune cells within the TME, as well as the actual tumor
cells. Within the last year, Liu and coworkers published a
study in which liposomes were used to encapsulate anti-
VEGF agents and were decorated with a CXCR4 antagonist
to target both angiogenic and immune responses in a hepa-
tocellular carcinoma model. CXCR4 is overexpressed in both
tumor and immune cells within the TME and served both as a
targeting ligand and a method to modulate the immune
response. They first tested these CXCR4-targeting liposomes
with sorafenib, a clinically approved anti-VEGF small mole-
cule drug, and found that combination therapy was more
effective than either treatment alone. They then replaced
sorafenib with anti-VEGF siRNA, which when combined with
the targeting liposomes, reduced the mean vessel density and
inhibited tumor growth as well as prevented TAM infiltration
into the tumor site [56].
Combination therapy can also target both the TME and
cancer cells themselves. Another group very recently reported
a multipart nanocarrier that can deliver multiple anticancer
agents and assemble into “drug-delivery depots” within the
TME. Their pH-sensitive carrier contained HA, which traffics
to tumor sites that overexpress the HA receptor CD44 as well
as hyaluronidase (HAase). When near the tumor site, HAase
cleaves HA, which triggers crosslinking of other components
of the nanocarrier, forming depots which are gradually
degraded by the acidity of the TME. When loaded with TNF-
related apoptosis-inducing ligand and the anti-angiogenic drug
cilengitide, these carriers homed to the tumor site, aggregated
into depots, provided a sustained release of their cargo,
decreased tumor vascularization, and significantly slowed
tumor growth with no toxic side effects. In addition, they
suggested that this nanoparticle platform also can be used to
carry a variety of cargo such as anticancer small molecule
drugs and immune modulating agents [57].
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cancer theranostics, in which a diagnostic agent also has
therapeutic benefits. They conjugated gold nanoparticles to a
chimeric tumor-targeting antibody, anti-GD2, which had
been modified to enhance NK cell function through inter-
action with the Fc receptor. The nanoparticles successfully
trafficked to GD2-expressing cancer cells and enhanced
computerized tomography contrast such that even small tu-
mors were visible on diagnostic scans. The Fc regions of the
antibodies bound to the Fc receptors on NK cell surfaces and
stimulated an immune response against the tumor cells.
Interestingly, the antibodies had a greater effect on NK
activation when conjugated to the nanoparticles than when
used alone, possibly due to the configuration of multiple
antibodies bound to each nanoparticle [58]. Thus, combina-
tion therapy can affect multiple TME aspects, target tumor
cells and the TME, or provide therapeutic effects as well as
diagnostics.2.5. Transporting antitumor agents using cell-based
nanotherapiesCells can be used as carriers for nanoparticles that are
either directly cytotoxic to the tumor and its surrounding
environment or nanoparticles which carry chemotherapeutic
agents. In most of the current cell-based nanotherapies, the
cell serves as a carrier for nanoparticles and their cargo. In
2006, Lee and coworkers coincubated T cells with
doxorubicin-loaded magnetic nanoparticles and induced par-
ticle uptake via electroporation. Although over half of the T
cells died from doxorubicin exposure within 15 h [59], other
studies were built upon this concept of using cells to deliver
nanoparticle-bound cargo [60,61].
Nanoparticles can be conjugated without a payload and
still have antitumor potential. In 2007, another group trans-
fected T cells with boron carbine nanoparticles and hypothe-
sized that the loaded cells could traffic to tumor sites, upon
which the boron nanoparticles would be irradiated and induce
tumor cell death [62]. One group conjugated iron-based
nanoparticles to NK cells and then injected them into
tumor-bearing mice. By placing an external magnet near the
tumor site, they were able to manipulate the movement of the
NK cells and increase their infiltration into the tumor 17-fold
[63]. Gold nanoparticle-mediated photothermal therapy is
being evaluated in clinical trials, but relies on passive accu-
mulation in leaky tumor vessels, which is insufficient in
poorly vascularized tumors. One group demonstrated that
monocytes and macrophages can endocytose gold nano-
particles and migrate to tumor sites. Once infiltrated into
breast cancer spheroids, the nanoparticles were heated with
near infrared light and induced photoablation of tumor cells
in vitro [64]. A few years later, another group used T cell
carriers to enhance gold nanoparticle delivery in vivo,
reporting a four-fold increase in accumulation at the tumor
site [65]. In these cases, the nanoparticles themselves assist in
killing cancerous cells without the use of a chemotherapeutic
drug.2.6. Utilizing nanoparticles to augment immune
therapiesAdoptive T cell transfer has been explored as a means to
eradicate solid tumors, but clinical results have been under-
whelming due to limited T cell expansion within the immu-
nosuppressive TME. Stephan et al., used a bioengineered
alginate matrix to harbor T cells and embedded silica particles
containing IL-15 superagonist and anti-CD3 to stimulate T
cell expansion within the matrix. The T cells migrated along
collagen fibers out of the matrix, and the stimulatory cytokines
and antibodies increased T cell proliferation 22-fold. When
implanted near the tumor site in a murine breast cancer model,
this system delivered localized immunotherapy and resulted in
tumor regression and increased survival due to greater
expansion and infiltration of T cells. This platform can be
modified to deliver other immune cells with antitumor prop-
erties or adjuvants to stimulate an immune response [66], and
demonstrates how bio-active materials can be used to deliver
cells which can modulate the TME.
Another group applied cell-based drug delivery to immune
adjuvants. Irvine et al., described a method of conjugating
PEGylated, maleimide-functionalized liposomes to free thiols
found on T cell surfaces. They were able to load T cells with
liposomes containing IL-15 and IL-21 and demonstrated that
these cytokines mimicked autocrine release kinetics and
resulted in a 10-fold increase in T cell expansion when
compared to the same nanoparticles systemically infused
instead of directly conjugated to T cells [60]. In this way, T
cells were sustained by cytokines from nanoparticles attached
to their cell surfaces instead of relying on systemic cytokine
doses.
3. Conclusion
Solid tumors are highly heterogeneous and grow in a
complex microenvironment consisting of the extracellular
matrix components, fibroblasts, vasculature and immune cells.
It is crucial to develop nanoparticles that can adapt the TME
and improve the selective targeting of anti-cancer drugs to
tumors [4,8,24,25]. The sensitivity of tumors to chemotherapy
is highly influenced by the surrounding tumor vasculature.
Vascular development is critical for tumor and growth pro-
gression and furthermore, anticancer drugs gain access to tu-
mors via blood vessels, making vasculature an attractive target
for improving cancer therapy. Recent advances have been
made to employ nanotechnology in tumor vasculature-targeted
drug delivery, enhancing the therapeutic efficacy of several
anticancer drugs. In addition, several studies have shown a
tumor vasculature targeted delivery system for integrated
combination therapy of vascular disrupting or anti-angiogenic
agents and chemotherapeutic agents, resulting in more effec-
tive and less toxic anticancer therapies.
One of the major structural components of the TME is the
ECM, with the most common constituents being collagen and
hyaluronic acid. Altered ECM processing and accumulation of
ECM with an abnormal composition play important roles in
76 E.L. Siegler et al. / Journal of Cellular Immunotherapy 2 (2016) 69e78tumor progression, invasion and metastasis [8,14,67]. To
suppress cancer growth and increase therapeutic efficacy,
cancer nanotherapeutics have been developed to deliver drugs
that target the altered physical properties of the ECM.
Nanoparticles can affect immune cells and their responses
within the TME. Cytokines encapsulated within various
nanoscale carriers provide more sustained release and reduced
toxicity while being systemically delivered to induce general
immune stimulation. Alternatively, nanomedicine can be
functionalized to enhance specific subpopulations of immune
cells, such as T cells, NK cells, and DCs. Nanoparticles can
carry cytotoxic agents or siRNA to either kill or modify
TAMs, respectively.
Combination therapy may be more effective than single
agents. Multiple TME components, such as immune cells and
vasculature, can be targeted using a nanoparticle carrier, or
both TME and cancer cells can be targeted at once. These
strategies often have been shown to work synergistically.
Combination therapy can also involve combining therapeutics
and diagnostics into one nanoparticle system. Combination
therapy is in its early stages and seems promising, but even
with highly functionalized nanoparticles, delivery is still often
reliant on the EPR effect, which is not always sufficient for
delivery into poorly perfused tumors.
Using immune cells as chaperones for drugs that target
tumor cells and the TME may increase accumulation in
otherwise inaccessible tumor sites. Most often, T cells are
used to carry either cytotoxic or immune-boosting agents to
tumors, but other immune cells can potentially be used as
“Trojan horses” as well. In other disease models, such as
Alzheimer's disease [68] and HIV [69], macrophages were
loaded with nanoparticles containing therapeutic agents and
were able to cross the blood brain barrier to deliver the cargo.
Macrophages may also prove to be useful in delivering loaded
nanoparticles to typically inaccessible tumor sites, including
those within the brain. Many different cell types can be used as
“pharmacytes” to deliver nanoparticle-conjugated small
molecule drugs, cytokines, siRNA, and myriad other agents in
order to overcome effects of the TME. Cell-based therapies
may prove to be the most effective anti-cancer treatment and
have shown promise in overcoming many hurdles presented by
the TME.
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